Novartis plans to file on Phase II data for panobinostat

Novartis AG (NYSE:NVS; SIX:NOVN) said it plans to submit regulatory applications worldwide for panobinostat by year end after reporting final data from a pivotal Phase II trial to treat relapsed or re...